Table 4.
Univariate Analysis of Factors Associated With GH and IGF-1 Response for 90 Eligible Studies (Effect Size)
| Variables | Effect Size on Response Rate |
|||||
|---|---|---|---|---|---|---|
| GH | 95% CI | P Value | IGF-1 | 95% CI | P Value | |
| Total number of patients | ||||||
| Accrued | −0.02 | (−0.1, 0.06) | .71 | −0.04 | (−0.12, 0.04) | .31 |
| Treated | 0.002 | (−0.10, 0.10) | .97 | −0.02 | (−0.1, 0.06) | .62 |
| Completed | −0.02 | (−0.14, 0.10) | .78 | −0.02 | (−0.12, 0.08) | .69 |
| Dropout rate (%) | 0.17 | (−0.10, 0.44) | .47 | −0.11 | (−0.35, 0.13) | .37 |
| Age, y | 0.12 | (−0.82, 1.06) | .81 | 0.37 | (−0.45, 1.19) | .39 |
| Year of study | 0.76 | (0.11, 1.41) | .03 | −0.17 | (−0.78, 0.44) | .59 |
| Baseline GH (n = 73) | −0.07 | (−0.38, 0.24) | .67 | 0.12 | (−0.13, 0.37) | .37 |
| Baseline IGF-1 (n = 55) | −0.03 | (−1.70, 1.64) | .97 | −0.02 | (−2.18, 2.14) | .98 |
| Dose duration, mo | 0.57 | (0.24, 0.90) | .001 | 0.35 | (0.06, 0.64) | .02 |
| SRL therapy naïve, % | −0.11 | (−0.21, −0.01) | .03 | −0.04 | (−0.12, 0.04) | .39 |
| TX naïve, % | −0.05 | (−0.17, 0.07) | .44 | −0.04 | (−0.14, 0.06) | .43 |
Abbreviations: CI, Confidence interval; TX, treatment.